P2Y12 Inhibitors
8 drugsAbout P2Y12
The P2Y12 receptor is a G protein-coupled receptor activated by adenosine diphosphate (ADP) that plays a key role in platelet aggregation and blood clot formation. Excessive platelet aggregation can lead to thrombotic events, such as heart attack and stroke. Thus, P2Y12 is a crucial target in cardiovascular medicine.
Human genetic studies provide strong validation for P2Y12 as a therapeutic target, with variants linked to platelet-type bleeding disorder 8 (score 0.85) and Nizon-Isidor syndrome (score 0.82). Loss-of-function variants are associated with increased risk of platelet disorders, suggesting activation of P2Y12 may be beneficial.
P2Y12 is targeted by 8 FDA-approved small molecule drugs, including PRASUGREL, TICAGRELOR (Brilinta), and KENGREAL. These drugs, developed by companies like AstraZeneca and Aurobindo Pharma, are vital in preventing and treating cardiovascular diseases by inhibiting ADP-mediated platelet activation.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Antiplatelet Drugs with only 3 trials.
Human Genetic Evidence Strong
Genetic evidence strongly supports P2Y12's role in platelet disorders, with a max genetic score of 0.85.
Strong genetic support suggests that clinical trials targeting P2Y12 have a higher likelihood of success.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 2 traits
- • Strong signal in hematologic disease, genetic, familial or congenital disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
14 totalGWAS and other genetic studies link P2RY12 to 14 diseases.
Loss-of-function causes disease; activation may help
🔗 Colocalization Evidence 4 strong
max H4: 1.00eQTL/pQTL signals for P2RY12 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
Eight companies have approved drugs targeting P2Y12, including Aurobindo Pharma and AMNEAL.
The presence of multiple players suggests a competitive market, requiring strong differentiation for new entrants.
Drug Modality Landscape
Modalities
Routes of Administration
P2Y12 is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Clinical Trials 545 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 103 | 93 | 7 | 3 | 93% |
| Phase 2 | 74 | 57 | 7 | 10 | 89% |
| Phase 3 | 116 | 78 | 16 | 22 | 83% |
| Phase 4 | 252 | 191 | 26 | 34 | 88% |
Top Sponsors
By Modality
Top Conditions
Drug Approval Timeline (1997 - 2025)
The first P2Y12-targeting drug was approved in 1997, with the most recent approval in 2025.
The continued approvals over 29 years indicate sustained interest and potential for further innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 8 companies competing
- • Market share by company
Full Drug Portfolio
- • All 8 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 8-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 266 clinical trials targeting P2Y12.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities